<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lantern Pharma Inc — News on 6ix</title>
<link>https://6ix.com/company/lantern-pharma-inc</link>
<description>Latest news and press releases for Lantern Pharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 11:50:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lantern-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835945578dffbe2df103adc.webp</url>
<title>Lantern Pharma Inc</title>
<link>https://6ix.com/company/lantern-pharma-inc</link>
</image>
<item>
<title>Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-to-debut-public-demonstration-of-withzetaai-a-platform-to-conquer-rare-cancers-on-april-30-following-aacr-2026-scientific-debut</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-to-debut-public-demonstration-of-withzetaai-a-platform-to-conquer-rare-cancers-on-april-30-following-aacr-2026-scientific-debut</guid>
<pubDate>Fri, 24 Apr 2026 11:50:00 GMT</pubDate>
<description>DALLAS, April 24, 2026--Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut</description>
</item>
<item>
<title>Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/emerging-data-for-lantern-pharmas-investigational-drug-lp-300-demonstrates-83-month-median-progression-free-survival-in-patients-with-egfr-l858r-lung-cancer-after-targeted-therapy-failure-with-no-added-toxicity</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/emerging-data-for-lantern-pharmas-investigational-drug-lp-300-demonstrates-83-month-median-progression-free-survival-in-patients-with-egfr-l858r-lung-cancer-after-targeted-therapy-failure-with-no-added-toxicity</guid>
<pubDate>Mon, 20 Apr 2026 12:05:00 GMT</pubDate>
<description>DALLAS, April 20, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to seek feedback on proposed protocol amendments to its ongoing Phase 2 HARMONIC™ clinical trial evaluating LP-300. The amendments are grounded in emerging clinical data demonstrating a meaningful and consistent progression-free survival signal in patients with EGFR Exon 21 L858R-mu</description>
</item>
<item>
<title>Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-launches-withzetaai-the-worlds-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery-and-development-subscriptions-now-open-debut-events-at-nasdaq-marketsite-on-416-and-at-aacr-2026-from-417-to-422</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-launches-withzetaai-the-worlds-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery-and-development-subscriptions-now-open-debut-events-at-nasdaq-marketsite-on-416-and-at-aacr-2026-from-417-to-422</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026,</description>
</item>
<item>
<title>Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-invites-investors-analysts-and-shareholders-to-experience-the-future-of-drug-discovery-via-a-live-demo-of-withzetaai-the-worlds-first-multi-agentic-co-scientist-for-rare-cancers-830-am-eastern-april-9-2026-105</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-invites-investors-analysts-and-shareholders-to-experience-the-future-of-drug-discovery-via-a-live-demo-of-withzetaai-the-worlds-first-multi-agentic-co-scientist-for-rare-cancers-830-am-eastern-april-9-2026-105</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform</description>
</item>
<item>
<title>Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase</description>
</item>
<item>
<title>Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-confirms-panna-sharma-continues-to-serve-as-president-and-ceo-alerts-investors-to-false-third-party-report</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its</description>
</item>
<item>
<title>Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-and-starlight-therapeutics-announce-fda-clearance-of-ind-for-a-planned-phase-1-pediatric-cns-cancer-trial-of-star-001</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-and-starlight-therapeutics-announce-fda-clearance-of-ind-for-a-planned-phase-1-pediatric-cns-cancer-trial-of-star-001</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory</description>
</item>
<item>
<title>Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-to-report-fourth-quarter-and-fiscal-year-2025-operating-and-financial-results-on-march-30th-2026-at-430-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-to-report-fourth-quarter-and-fiscal-year-2025-operating-and-financial-results-on-march-30th-2026-at-430-pm-et</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS--(BUSINESS WIRE)-- Lantern Pharma</description>
</item>
<item>
<title>Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-7th-glioblastoma-134500155</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-7th-glioblastoma-134500155</guid>
<pubDate>Tue, 10 Feb 2026 13:45:00 GMT</pubDate>
<description>DALLAS, February 10, 2026--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026</description>
</item>
<item>
<title>Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharmas-lp-284-receives-130000815</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharmas-lp-284-receives-130000815</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>DALLAS, January 20, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas.</description>
</item>
<item>
<title>Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-announces-establishing-center-140000919</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-announces-establishing-center-140000919</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>DALLAS, January 12, 2026--A.I. center of excellence - Lantern Pharma</description>
</item>
<item>
<title>Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-additional-positive-133500318</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-additional-positive-133500318</guid>
<pubDate>Wed, 03 Dec 2025 13:35:00 GMT</pubDate>
<description>DALLAS, December 03, 2025--LP-184 Clinical Insights, KOL Webinar & Future Plans</description>
</item>
<item>
<title>Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-third-quarter-133000991</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-reports-third-quarter-133000991</guid>
<pubDate>Thu, 13 Nov 2025 13:30:00 GMT</pubDate>
<description>DALLAS, November 13, 2025--Q3 Press Release - BTM</description>
</item>
<item>
<title>Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-engages-street-national-140000846</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-engages-street-national-140000846</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>NEW YORK, NY / ACCESS Newswire / November 7, 2025 / New to The Street, one of America's leading business television and multi-platform media brands, today announced a comprehensive media partnership with Lantern Pharma Inc. (NASDAQ:LTRN), an artificial ...</description>
</item>
<item>
<title>Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-report-third-quarter-130000869</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-report-third-quarter-130000869</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>DALLAS, November 06, 2025--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET</description>
</item>
<item>
<title>Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-ai-driven-120000657</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-ai-driven-120000657</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>DALLAS, October 30, 2025--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.</description>
</item>
<item>
<title>Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-presents-lp-284-124900557</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-presents-lp-284-124900557</guid>
<pubDate>Tue, 28 Oct 2025 12:49:00 GMT</pubDate>
<description>DALLAS, October 28, 2025--LP-284 at 25th LL&M Congress & CMR</description>
</item>
<item>
<title>Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-thinkequity-conference-120000549</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-present-thinkequity-conference-120000549</guid>
<pubDate>Fri, 24 Oct 2025 12:00:00 GMT</pubDate>
<description>DALLAS, October 24, 2025--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025</description>
</item>
<item>
<title>Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-lp-184-phase-122900637</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/lantern-pharma-lp-184-phase-122900637</guid>
<pubDate>Tue, 16 Sep 2025 12:29:00 GMT</pubDate>
<description>DALLAS, September 16, 2025--Clinical Trial Results, LP-184</description>
</item>
<item>
<title>IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN)</title>
<link>https://6ix.com/company/lantern-pharma-inc/news/ibn-announces-latest-episode-of-the-biomedwire-podcast-featuring-panna-sharma-ceo-of-ai-driven-biotech-focused-on-challenging-and-rare-cancers-lantern-pharma-inc-ltrn</link>
<guid isPermaLink="true">https://6ix.com/company/lantern-pharma-inc/news/ibn-announces-latest-episode-of-the-biomedwire-podcast-featuring-panna-sharma-ceo-of-ai-driven-biotech-focused-on-challenging-and-rare-cancers-lantern-pharma-inc-ltrn</guid>
<pubDate>Wed, 10 Sep 2025 12:00:00 GMT</pubDate>
<description>AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancem</description>
</item>
</channel>
</rss>